title: Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.
abstract: A patient with Non-Hodgkin's lymphoma is reported, in which reactivation of the hepatitis B virus was achieved from treatment with rituximab. The patient's HBs antigens were positive on admission, and she tested positive for HBs, HBe, and HBc antibodies, and negative for the HBe antigens. She was treated with a regimen of three courses of rituximab-containing anti-cancer drugs and one course of combined anti-cancer drugs. Throughout these chemotherapy courses, prednisolone was not given. After the fourth course of chemotherapy with the third rituximab she developed hepatic dysfunction, and the serum titers of HBs and HBc antibodies suddenly decreased. After administration of lamivudine, however, she gradually recovered from liver failure.
authors.affiliation: Department of Internal Medicine, Hakodate Municipal Hospital, Hakodate, Japan.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tsutsumi
authors.forename: Takahito
authors.initials: T
authors.lastname: Kawamura
authors.forename: Shin
authors.initials: S
authors.lastname: Saitoh
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamada
authors.forename: Shinji
authors.initials: S
authors.lastname: Obara
authors.forename: Takuya
authors.initials: T
authors.lastname: Miura
authors.forename: Hiroe
authors.initials: H
authors.lastname: Kanamori
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Imamura
authors.forename: Nobuo
authors.initials: N
authors.lastname: Masauzi
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D017093:Liver Failure / Q000139:chemically induced / Q000821:virology; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D000069283:Rituximab; D012698:Serologic Tests; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D019259:Lamivudine; D000069283:Rituximab